Stabilization of p73 by nuclear IkappaB kinase-alpha mediates cisplatin-induced apoptosis.
In response to DNA damage, p53 and its homolog p73 have a function antagonistic to NF-kappaB in deciding cell fate. Here, we show for the first time that p73, but not p53, is stabilized by physical interaction with nuclear IkappaB kinase (IKK)-alpha to enhance cisplatin (CDDP)-induced apoptosis. CDDP caused a significant increase in the amounts of nuclear IKK-alpha and p73alpha in human osteosarcoma-derived U2OS cells. Ectopic expression of IKK-alpha prolonged the half-life of p73 by inhibiting its ubiquitination and thereby enhancing its transactivation and pro-apoptotic activities. Consistent with these results, small interfering RNA-mediated knockdown of endogenous IKK-alpha inhibited the CDDP-mediated accumulation of p73alpha. The kinase-deficient mutant form of IKK-alpha interacted with p73alpha, but failed to stabilize it. Furthermore, CDDP-mediated accumulation of endogenous p73alpha was not detected in mouse embryonic fibroblasts (MEFs) prepared from IKK-alpha-deficient mice, and CDDP sensitivity was significantly decreased in IKK-alpha-deficient MEFs compared with wild-type MEFs. Thus, our results strongly suggest that the nuclear IKK-alpha-mediated accumulation of p73alpha is one of the novel molecular mechanisms to induce apoptotic cell death in response to CDDP, which may be particularly important in killing tumor cells with p53 mutation.
Furuya
Kazushige
K
Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan; Second Department of Surgery, Yamanashi University School of Medicine, Yamanashi 409-3898, Japan.
Ozaki
Toshinori
T
Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Hanamoto
Takayuki
T
Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Hosoda
Mitsuchika
M
Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Hayashi
Syunji
S
Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Barker
Philip A
PA
Montreal Neurological Institute, McGill University, Montreal, Quebec H3A 2B4, Canada.
Takano
Kunio
K
Second Department of Surgery, Yamanashi University School of Medicine, Yamanashi 409-3898, Japan.
Matsumoto
Masahiko
M
Second Department of Surgery, Yamanashi University School of Medicine, Yamanashi 409-3898, Japan.
Nakagawara
Akira
A
Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan. Electronic address: akiranak@chiba-cc.jp.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D019556:COS Cells; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D002522:Chlorocebus aethiops; D002945:Cisplatin / Q000494:pharmacology*; D004268:DNA-Binding Proteins / Q000737:chemistry / Q000502:physiology*; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D051550:I-kappa B Kinase / Q000378:metabolism*; D051379:Mice; D009687:Nuclear Proteins / Q000737:chemistry / Q000502:physiology*; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000737:chemistry / Q000502:physiology*
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D051550:I-kappa B Kinase; D002945:Cisplatin